UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM 8-K
 
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported) June 14, 2005
 
 
NOVADEL PHARMA INC.
(Exact Name of Registrant as Specified in Its Charter)
 
         
Delaware
 
001-32177
 
22-2407152
(State or other jurisdiction
of incorporation)
 
(Commission File No.)
 
(I.R.S. Employer
Identification No.)
 
25 Minneakoning Road
Flemington, New Jersey 08822
(Address of principal executive offices) (Zip Code)
 
(908) 782-3431
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 

Item 2.02. Results of Operations and Financial Condition.
 
On June 14, 2005, NovaDel Pharma Inc. (the “Company”) issued a press release to report its financial results for the quarter ended April 30, 2005. A copy of the press release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.
 
(c) Exhibits.

99.1  
Press release dated June 14, 2005, titled “NovaDel Reports Third Fiscal Quarter and Nine Month Results.”

This press release is being furnished pursuant to Item 9.01 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
 
 
2
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  NovaDel Pharma Inc.
 
 		  
 		  
 
  By:   /s/  Jean W. Frydman
 
Jean W. Frydman
  Title: Vice President and General Counsel
Date: June 20, 2005  

 
3
 
EXHIBIT INDEX

     
Exhibit
 
Description
     
99.1
 
Press release dated June 14, 2005, titled “NovaDel Reports Third Fiscal Quarter and Nine Month Results.”


 
4